However, inhibiting IL6 activity with neutralizing antibody may not be an ideal approach for the cancer treatment because the therapeutic efficacy not only depends on the antibody-to-cytokine binding affinity, but also the initial IL6 concentrations in the CRC patients [41], which may be a clinical challenge. The gene discussed is IL6; the disease is cancer.